Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia

Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and a better safety profile compared to warfarin. Objectives: (1) To describe the characterist...

ver descrição completa

Detalhes bibliográficos
Autores: Gómez Lumbreras, Ainhoa, Cortés Martínez, Jordi|||0000-0002-3764-0795, Giner Soriano, Maria, Quijada Manuitt, Mª Angeles, Morros Padrós, Rosa
Formato: artículo
Fecha de publicación:2018
País:España
Recursos:Universitat Politècnica de Catalunya (UPC)
Repositorio:UPCommons. Portal del coneixement obert de la UPC
Idioma:inglés
OAI Identifier:oai:upcommons.upc.edu:2117/132728
Acesso em linha:https://hdl.handle.net/2117/132728
https://dx.doi.org/10.1177/1074248418778544
Access Level:acceso abierto
Palavra-chave:Combinatorial probabilities
Sampling (Statistics)
apixaban
anticoagulants
drug use review
medication adherence
electronic health records
Probabilitats
Mostreig (Estadística)
Classificació AMS::60 Probability theory and stochastic processes::60C05 Combinatorial probability
Classificació AMS::62 Statistics::62D05 Sampling theory, sample surveys
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica discreta::Combinatòria
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica aplicada a les ciències
id ES_52e8d6b8f02935280a7eeff9e289e9f4
oai_identifier_str oai:upcommons.upc.edu:2117/132728
network_acronym_str ES
network_name_str España
repository_id_str
spelling Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in CataloniaGómez Lumbreras, AinhoaCortés Martínez, Jordi|||0000-0002-3764-0795Giner Soriano, MariaQuijada Manuitt, Mª AngelesMorros Padrós, RosaCombinatorial probabilitiesSampling (Statistics)apixabananticoagulantsdrug use reviewmedication adherenceelectronic health recordsProbabilitatsMostreig (Estadística)Classificació AMS::60 Probability theory and stochastic processes::60C05 Combinatorial probabilityClassificació AMS::62 Statistics::62D05 Sampling theory, sample surveysÀrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica discreta::CombinatòriaÀrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica aplicada a les ciènciesApixaban is a direct oral anticoagulant, which inhibits factor Xa. It has demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and a better safety profile compared to warfarin. Objectives: (1) To describe the characteristics of patients with nonvalvular atrial fibrillation beginning treatment with apixaban, (2) to analyze concomitant prescriptions of medications that could potentially interact with apixaban, (3) to evaluate the level of appropriate usage according to the recommended dosage, and (4) to estimate the level of apixaban persistence among naive and non-naive patients. Methods: Cohort study using data from primary care (System for Research in Primary Care database, users of the Institut Catala` de la Salut; Catalonia, Spain) from August 2013 to December 2015. Results: Mean age for apixaban-treated patients was 71.8 years (standard deviation ¼ 11.1) and 55.6% were male. In all, 3.2% of patients receiving apixaban were taking drugs described as potentially related to either pharmacokinetic or pharmacodynamic interactions. According to the summary of product characteristics, 81.1% of patients with a recommended dose of 2.5 mg twice daily and 51.8% with a recommended dose of 5 mg twice daily actually took this dose. After 1 year of followup, 62.6% of the apixaban users showed good adherence. Conclusion: The prescribed dose of apixaban did not fully follow the recommended dose, particularly in patients who were treatment naive. Patients with a prior history of anticoagulant treatment were more likely to remain persistent to treatment with apixaban.Peer Reviewed20182018-05-2320192019-05-08journal articlehttp://purl.org/coar/resource_type/c_6501AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/2117/132728https://dx.doi.org/10.1177/1074248418778544reponame:UPCommons. Portal del coneixement obert de la UPCinstname:Universitat Politècnica de Catalunya (UPC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:upcommons.upc.edu:2117/1327282026-05-27T15:37:01Z
dc.title.none.fl_str_mv Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
title Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
spellingShingle Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
Gómez Lumbreras, Ainhoa
Combinatorial probabilities
Sampling (Statistics)
apixaban
anticoagulants
drug use review
medication adherence
electronic health records
Probabilitats
Mostreig (Estadística)
Classificació AMS::60 Probability theory and stochastic processes::60C05 Combinatorial probability
Classificació AMS::62 Statistics::62D05 Sampling theory, sample surveys
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica discreta::Combinatòria
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica aplicada a les ciències
title_short Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
title_full Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
title_fullStr Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
title_full_unstemmed Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
title_sort Characteristics of apixaban-treated patients, evaluation of the dose prescribed, and the persistence of treatment: a cohort study in Catalonia
dc.creator.none.fl_str_mv Gómez Lumbreras, Ainhoa
Cortés Martínez, Jordi|||0000-0002-3764-0795
Giner Soriano, Maria
Quijada Manuitt, Mª Angeles
Morros Padrós, Rosa
author Gómez Lumbreras, Ainhoa
author_facet Gómez Lumbreras, Ainhoa
Cortés Martínez, Jordi|||0000-0002-3764-0795
Giner Soriano, Maria
Quijada Manuitt, Mª Angeles
Morros Padrós, Rosa
author_role author
author2 Cortés Martínez, Jordi|||0000-0002-3764-0795
Giner Soriano, Maria
Quijada Manuitt, Mª Angeles
Morros Padrós, Rosa
author2_role author
author
author
author
dc.subject.none.fl_str_mv Combinatorial probabilities
Sampling (Statistics)
apixaban
anticoagulants
drug use review
medication adherence
electronic health records
Probabilitats
Mostreig (Estadística)
Classificació AMS::60 Probability theory and stochastic processes::60C05 Combinatorial probability
Classificació AMS::62 Statistics::62D05 Sampling theory, sample surveys
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica discreta::Combinatòria
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica aplicada a les ciències
topic Combinatorial probabilities
Sampling (Statistics)
apixaban
anticoagulants
drug use review
medication adherence
electronic health records
Probabilitats
Mostreig (Estadística)
Classificació AMS::60 Probability theory and stochastic processes::60C05 Combinatorial probability
Classificació AMS::62 Statistics::62D05 Sampling theory, sample surveys
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica discreta::Combinatòria
Àrees temàtiques de la UPC::Matemàtiques i estadística::Matemàtica aplicada a les ciències
description Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and a better safety profile compared to warfarin. Objectives: (1) To describe the characteristics of patients with nonvalvular atrial fibrillation beginning treatment with apixaban, (2) to analyze concomitant prescriptions of medications that could potentially interact with apixaban, (3) to evaluate the level of appropriate usage according to the recommended dosage, and (4) to estimate the level of apixaban persistence among naive and non-naive patients. Methods: Cohort study using data from primary care (System for Research in Primary Care database, users of the Institut Catala` de la Salut; Catalonia, Spain) from August 2013 to December 2015. Results: Mean age for apixaban-treated patients was 71.8 years (standard deviation ¼ 11.1) and 55.6% were male. In all, 3.2% of patients receiving apixaban were taking drugs described as potentially related to either pharmacokinetic or pharmacodynamic interactions. According to the summary of product characteristics, 81.1% of patients with a recommended dose of 2.5 mg twice daily and 51.8% with a recommended dose of 5 mg twice daily actually took this dose. After 1 year of followup, 62.6% of the apixaban users showed good adherence. Conclusion: The prescribed dose of apixaban did not fully follow the recommended dose, particularly in patients who were treatment naive. Patients with a prior history of anticoagulant treatment were more likely to remain persistent to treatment with apixaban.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018-05-23
2019
2019-05-08
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
AM
http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/2117/132728
https://dx.doi.org/10.1177/1074248418778544
url https://hdl.handle.net/2117/132728
https://dx.doi.org/10.1177/1074248418778544
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:UPCommons. Portal del coneixement obert de la UPC
instname:Universitat Politècnica de Catalunya (UPC)
instname_str Universitat Politècnica de Catalunya (UPC)
reponame_str UPCommons. Portal del coneixement obert de la UPC
collection UPCommons. Portal del coneixement obert de la UPC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408080955965440
score 15.301603

Registos relacionados